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travenous histamine (a vasopressorl. Thrombi were present in 19 of 34 aor-
tic plaques but none of 11 aortic sections from the normal rabbits. The 34
plaques and 11 normal sections were stained with antibody to tissue factor.
While none of the normal specimens had luminal surface tissue factor, it was
found on the surface of 17/19 (87%) of plaques with thrombi and 7/15 (45%)
of plaques without thrombi (p = 0.009).
r- p<O.001 -I
I r- p<0.01--,
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Conclusion: Plaques associated with thrombi were significantly more likely
to have luminal tissue factor than those without thrombi. These findings sup-
port the importance of tissue factor as a link between atherosclerosis and
thrombosis.
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Restoration of Thromboresistance in Injured Aortic
Segments by a Novel Nitric Oxide Donor
Tasneem Z. Naqvi, Michael C. Fishbein, Bojan Cercek, Arun M. Thomas, Mia
D. Molloy, Lina Badimon, Prediman K. Shah. Thomas C. Hutsell. Sanjay Kaul.
Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA: Comedicus
Incorporated, Minneapolis, MN
Endothelium-derived nitric oxide (NO) is one of the principal mediators of
thromboresistance in intact blood vessels. To determine whether repletion
of NO would restore thromboresistance in injured arterial segments, we in-
vestigated the effect of a novel short-lived NO donor - NO adduct of N,N'-
dimethylhexanediamine (DMHD/NO) on arterial injury-induced thrombosis
in an ex vivo rabbit carotid-jugular arteriovenous shunt model. Segments
of porcine aortic subendothelium (endothelium-deficient but intact internal
elastic lamina) and media, simulating mild and deep arterial injury, respec-
tively, were placed in a Badimon perfusion chamber and exposed to flowing
arterial blood from hypercholesterolemic (He) rabbits (cholesterol of 431 ±
187 mg/dL. n = 5) for 10 minutes at a shear rate of 1700/s (typical of mild
coronary stenosis). Thrombus volume was quantified in control and treated
segments by morphometry of histological sections. Treatment consisted of
DMHD/NO 10.01 /tM) and phosphate buffered saline as control. Thrombus
formation was minimal in subendothelium (8 ± 4/tm3//tm 2 of exposed area),
whereas media developed large thrombi (78 ± 15 /tm3//tm 2 (p = O.OOli.
DMHD/NO strikingly reduced thrombus volume in media by 85 ± 5% to 15
± 6 /tm3//tm 2, thereby effectively reversing thrombus formation to that in
subendothelium. Infusion of saline had no effect on thrombus formation.
Mean arterial pressure fell by about 3% after infusion of DMHD/NO.
Conclusion: In this ex vivo model of arterial thrombosis 1) deeply injured-
arterial segments (media) were highly thrombogenic and mildly injured-
arterial segments Isubendotheliuml were relatively thromboresistant. and 2)
DM HD/NO, a novel nitric oxide donor, effectively restored thromboresistance
in deeply injured-arterial segments without producing significant systemic
hemodynamic effects.
The presence of residual mural thrombus (MT) predisposes to recurrent
thrombotic vessel occlusion. To compare the benefits of different antithrom-
botic and anti platelet agents we studied the growth of thrombus on a pre-
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Comparative Effects of Heparin, Aspirin, and Hirudin
on Thrombus Growth on Fresh Mural Thrombus:
Deaggregation of Mural Thrombus by Specific
Thrombin Inhibition
Beat J. Meyer 1, Juan J. Badimon, John 1. Fallon, Valentin Fuster, James
H. Chesebro, Lina Badimon 1University Hospital Bern, Switzerland: Mount Sinai
Medical Center. New York
N Acute Restenosis Repeat PTA Long-term
Success Stent. Surgery Success
Group I 26 80% 82% 76% 30%
Group II 13 100% 23% 23% 84%
p-vaJue 0.17 <0.001 <0.008 <0.005
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Differential Expression of Tissue Factor Protein in
Directional Atherectomy Specimens from Patients
with Stable and Unstable Coronary Syndromes
Brian H. Annex, Stephen M. Denning, Keith Channon, Michael H. Sketch, Jr.,
Richard S. Stack, Kevin G. Peters Duke University Medical Center. Durham, NC
Tissue factor (TF) is a cell membrane-associated protein that catalyzes the
rate-limiting step of the exttinsic coagulation pathway, which is the major
source of thrombin production in-vivo. To examine the potential role that
TF may play in the pathogenesis of different coronary syndromes, we stud-
ied directional coronary atherectomy specimens ftom 57 patients, using im-
munohistochemical techniques. Patients were classified according to their
admission diagnosis as having either an unstable coronary syndrome, which
required the presence of rest angina or post-infarction 1<1 week) angina,
or stable coronary syndromes which included stable, progressive and new-
onset angina without rest chest pain. Lesions were also classified as a de-
novo or a restenosis lesion. Frozen sections were examined for the presence
of TF using a murine IgG monoclonal antibody against human tissue fac-
tor. Samples were read independently by two investigators without knowl-
edge of the clinical information. The results were expressed dichotomously
as positive or negative using human skin sections as a positive control and
a nonsense murine monoclonal antibody as a negative control. Statistical
analysis were performed using a Chi-Square or Fischer's Exact Test. For the
entire study group, TF was detected in 15 (45%) of 33 patients with unstable
coronary syndromes versus only 3 (13%1 of 24 patients with stable coronary
syndromes; p :s 0.02. Moreover, within the subgroup of patients with unsta-
ble coronary syndromes, TF protein was detected in 14 (61 %) of 23 patients
with de-novo lesions versus only 1 (10%) of 10 patients with rest angina from
a restenosis lesion; p :s 0.01. An additional 7 patients with stable coronary
syndromes due to a restenosis lesion were also all negative for TF, for an
overall incidence of only 1 (6%1 of 17 restenosis lesions.
In conclusion, tissue factor is readily detected in atherectomy specimens
from de-novo lesions in patients with unstable coronary syndromes, sug-
gesting a role for this protein in the pathogenesis of this disease process.
Conversely, tissue factor is rarely detected in patients with restenosis lesions
even if the clinical presentation is an unstable coronary syndrome. These re-
sults may have implications in regard to the management of patients with
unstable angina from de-novo lesions and all patients with recurrent symp-
toms from restenosis lesions.
In a subset of pts with restenosis after PTA, repeat balloon angioplasty (N
= 14) resulted in a 100% restenosis; however, central vein stenting (N = 8)
was associated with recurrent restenosis in only 38% (p < 0.0005).
Conclusion: PTA of central venous occlusions in dialysis patients is asso-
ciated with a very high restenosis rate, especially in patients with prior an-
gioplasty. Because stenting has an excellent acute success rate and lower
restenosis rate, it appears to be a better treatment option in these patients.
Atherosclerotic plaque disruption and thrombosis are now recognized as ma-
jor causes of acute coronary syndromes. Tissue factor may playa central role
in linking plaque disruption to thrombus formation. We utilized an atheroscle-
rotic rabbit model of plaque disruption and thrombosis to determine the re-
lationship between luminal surface tissue factor and arterial thrombi.
Triggering was attempted in 11 atherosclerotic rabbits and 5 normal rab-
bits using only intraperitoneal Russell viper venom (a procoagulant) and in-
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